In Week of Mar 28, 2026, Glenmark Pharmaceuticals Ltd (Pharma - Formulators) is outperforming Nifty 500 with +19.6% relative strength. Fundamentals: Weak. On a 7-week streak.
Weekly presence in the outperformers list. Green = beating Nifty 500 by 10%+ that week.
Based on Q3 FY26 (December 2025 quarter) earnings • Updated Feb 22, 2026
What: Domestic business growing at 15.8% vs market growth of 10.9%, outperforming by 500 bps
“Glenmark's domestic business recorded a growth of 15.8% in the third quarter and 13% as per MAT December 2025 compared to the overall market growth of 10.9%”
What: Favorable forex movement across key geographies boosting international revenue
“The business growth was helped in part by the currency depreciation across our key geographies”
What: Targeting gross debt zero by March 2026, reducing interest costs
“We continue to remain net cash positive and are on track to target the gross debt zero by March 26”
Earnings deceleration risks from management commentary
Trigger: Continued unfavorable product mix shift
Management view: Our gross margin in current quarter was impacted by the product mix. However, we saw a good operating leverage which helped overall margins.
Monitor: OPM trend vs product mix changes
Trigger: Escalation of geopolitical tensions
Management view: While the overall geopolitical uncertainty remains prevalent
Monitor: International revenue growth consistency
Key quotes from recent conference calls
“Glenmark's domestic business recorded a growth of 15.8% in the third quarter and 13% as per MAT December 2025 compared to the overall market growth of 10.9% in the third quarter and 8.3% as per MAT December. Glenmark continues to outperform the overall market in its key therapeutic areas. — Management”
“The business growth was helped in part by the currency depreciation across our key geographies. However, our base business performance continues to remain strong especially in key blended markets with our gross margin in current quarter was impacted by the product mix. However, we saw a good operating leverage which helped overall margins. — Anurag”
“We continue to remain net cash positive and are on track to target the gross debt zero by March 26. Multiple initiatives are ongoing to... — Anurag”
“At IID level we are on track to deliver our guidance of 23% in a sustainable basis — Management”
Forward-looking targets from management for Next 2-4 quarters
OPM Guidance
23%
Key Milestones
• Gross debt zero by March 2026
• 23% OPM sustainably
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | +15% | +3% | Stable |
| PAT (Net Profit) | +16% | +2% | Stable |
| OPM | 22.0% | +400 bps | Volatile |
The above analysis is parsed from publicly available earnings call transcripts. This is educational research only — not investment advice. Last updated Feb 22, 2026.
Based on publicly available financial data. This is educational research, not investment advice.
Glenmark Pharmaceuticals Ltd's latest quarterly results (Dec 2025) show
Glenmark Pharmaceuticals Ltd's profit is growing with an stable trend.
Glenmark Pharmaceuticals Ltd's revenue growth trend is stable.
Glenmark Pharmaceuticals Ltd's operating margin is volatile.
Glenmark Pharmaceuticals Ltd's long-term compounding rates
Glenmark Pharmaceuticals Ltd's earnings growth is stable with mixed signals on a sequential basis.
Glenmark Pharmaceuticals Ltd's trailing twelve month (TTM) performance
Glenmark Pharmaceuticals Ltd appears fairly valued based on our fair value analysis.
Glenmark Pharmaceuticals Ltd's current PE ratio is 22.6x.
Glenmark Pharmaceuticals Ltd's current PE is 22.6x.
Glenmark Pharmaceuticals Ltd's price-to-book ratio is 6.4x.
Glenmark Pharmaceuticals Ltd is rated Weak with a fundamental score of 33.45/100. This score is calculated from objective financial metrics
Glenmark Pharmaceuticals Ltd has a debt-to-equity ratio of N/A.
Glenmark Pharmaceuticals Ltd's return ratios over recent years
Glenmark Pharmaceuticals Ltd's operating cash flow is negative (FY2025).
Glenmark Pharmaceuticals Ltd's current dividend yield is 0.12%.
Glenmark Pharmaceuticals Ltd's shareholding pattern (Dec 2025)
Glenmark Pharmaceuticals Ltd's promoter holding has increased recently.
Glenmark Pharmaceuticals Ltd has been outperforming Nifty 500 for 7 consecutive weeks, indicating building momentum.
Glenmark Pharmaceuticals Ltd is a re-entry — it briefly dropped off the outperformance list but has now returned. Re-entries can signal renewed strength.
Glenmark Pharmaceuticals Ltd has 3 key growth catalysts identified from recent earnings analysis
Glenmark Pharmaceuticals Ltd has 2 key risks worth monitoring
In Q3 FY26 (December 2025 quarter), Glenmark Pharmaceuticals Ltd's management highlighted
Glenmark Pharmaceuticals Ltd's management has provided the following forward guidance for Next 2-4 quarters
Based on quantitative research signals, here is why Glenmark Pharmaceuticals Ltd may be worth studying
Glenmark Pharmaceuticals Ltd investment thesis summary:
Glenmark Pharmaceuticals Ltd's forward outlook based on current data signals
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.
